29 completed, 15 recruiting, 14 unknown, 9 active not recruiting. 30 Phase 2, 24 Not applicable, 21 Phase 3, 5 Phase 4, 4 Phase 1.
Follow Maintenance: new trials by email Literature Review of Maintenance trials Research Report on Maintenance
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma teclistamab+daratumumab followed by talquetamab+daratumumab followed by duration treatment with daratumumab and lenalidomide extended/maintenance, melphalan (MEL)-based hematopietic stem cell transplantation (HSCT) followed by drug therapy - Multiple Myeloma (MM) | Phase 2 | Not yet recruiting | University of Arkansas | 50 | 2027-03-01 | 2026-09-02 |
| A Pragmatic Clinical Trial to Prevent Relapse for Myeloid Malignancies With Measurable Disease Prior to Allogeneic Transplant Maintenance Therapy, No intervention - Myeloid Disorders, Myelodysplastic Syndromes | Phase 2 | Not yet recruiting | Medical College of Wisconsin | 450 | 2026-12-01 | 2026-10-13 |
| Becotatug Vedotin Plus Pucotenlimab and Capecitabine Followed by Concurrent Chemoradiotherapy-Immunotherapy for Locally Advanced Squamous Cell Carcinoma of the Anal Canal Induction therapy, Concurrent chemoradiotherapy-immunotherapy, Maintenance therapy - Squamous Cell Carcinoma of the Anal Canal | Phase 2 | Not yet recruiting | Wang Xin | 34 | 2026-09-20 | 2026-09-08 |
| Adebrelimab Combined With Chemoradiotherapy in Patients With Large Bulky Stage III Unresectable Non-Small Cell Lung Cancer After chemoimmunotherapy induction, followed by concurrent/sequential chemoradiotherapy and subsequent immune consolidation and maintenance therapy., adebrelimab,Radiation Therapy,Radiotherapy - NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 3 | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 204 | 2026-05-01 | 2026-05-01 |
| VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML Gilteritinib + Azacitidine + Venetoclax, Cytarabine + Daunorubicin (or Idarubicin) + Gilteritinib, Re-induction Therapy - AML, Adult | Phase 3 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 300 | 2026-04-30 | 2026-03-25 |
| Adding Asciminib to Usual Treatment for Adults With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia Induction Phase, Re-Induction Phase, Post-Remission - Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia, CD19+ Acute Leukemia | Phase 2 | Enrolling by invitation | SWOG Cancer Research Network | 55 | 2026-04-13 | 2026-10-05 |
| Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia VDCLP+V, 2VIP, Consolidation Therapy - Acute Lymphoblastic Leukemia, Adult | Not applicable | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 43 | 2026-04-08 | 2026-08-10 |
| Lubiprostone Combined With Maintenance Therapy for Prevention of Postoperative Recurrence in Peritoneal Metastatic Colorectal Cancer maintenance therapy plus lubiprostone, maintenance therapy - Colorectal Cancer Metastatic, Peritoneal (Metastatic) Cancer | Phase 2 | Not yet recruiting | Sun Yat-sen University | 124 | 2026-02-24 | 2026-02-12 |
| Systemic Therapy in Combination with Stereotactic Radiotherapy in Patients with Metastatic Colorectal Cancer Up to 10 Metastatic Sites Stereotactic body radiation therapy (SBRT), Maintenance therapy (CAP-B or 5-FU/LV plus bevacizumab.) - Metastatic Colorectal Cancer, Oligometastatic Disease | Phase 2 | Suspended | UMC Utrecht | 93 | 2025-12-01 | 2025-03-28 |
| DV+BCG in HER2-Expressing, BCG-Naïve High-Risk NMIBC Active Comparator: BCG induction and maintenance, DV + BCG induction and maintenance - Bladder (Urothelial, Transitional Cell) Cancer, NMIBC | Phase 3 | Recruiting | Fudan University | 182 | 2025-12-01 | 2026-07-21 |
| Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung Cancer Carboplatin, Paclitaxel, Cemiplimab - Stage III NSCLC | Phase 2 | Recruiting | Intergroupe Francophone de Cancerologie Thoracique | 152 | 2025-11-07 | 2026-08-11 |
| Serplulimab, Chidamide, and Rituximab Followed by Sequential R-CHOP for Newly Diagnosed Elderly MYC/BCL2 Double-Expressor DLBCL SCR Regimen Sequential with R-CHOP and Maintenance Therapy - Newly Diagnosed MYC/BCL2 Double-expressor DLBCL | Phase 2 | Active not recruiting | Sun Yat-sen University | 30 | 2025-10-30 | 2026-04-20 |
| Orelabrutinib as Consolidation and Maintenance Therapy in Treatment-Naïve MZL. Orelabrutinib Consolidation and Maintenance Therapy - Marginal Zone Lymphoma (MZL) | Phase 2 | Recruiting | The First Affiliated Hospital of Soochow University | 23 | 2025-10-24 | 2026-01-28 |
| Zanubrutinib, Obinutuzumab, and Lenalidomide (ZGR) in the Treatment of Newly Diagnosed Splenic B-cell Lymphoma With Prominent Nucleoli (SBLPN): A Prospective, Open-label, Single-arm Clinical Trial Induction Therapy, Maintenance Therapy - Splenic B-cell Lymphoma/Leukaemia With Prominent Nucleoli，SBLPN | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 47 | 2025-09-04 | 2025-12-18 |
| Examining Effects of Active Plant Engagement on College Student Well-Being and Performance Active Plant Engagement - Perceived Stress, State Anxiety | Not applicable | Active not recruiting | Colorado State University | 87 | 2025-08-22 | 2026-01-13 |
| High Dose (HD) Aflibercept Switch in Neovascular Age-related Macular Degeneration (nAMD): to Load or Maintain (HEIRLOOM) Maintenance - Wet Age-related Macular Degeneration (wAMD) | Phase 3 | Not yet recruiting | Clinique de Retine de l'est | 180 | 2025-08-20 | 2025-08-19 |
| Efficacy of Stereotactic Body Radiotherapy (SBRT) Combined With Maintenance Therapy Compared to Maintenance Therapy Alone in Advanced Pancreatic Cancer Stereotactic Body Radiotherapy (SBRT) with maintenance therapy, Maintenance therapy - Pancreatic Cancer Non-resectable | Phase 2 | Recruiting | Shandong Cancer Hospital and Institute | 24 | 2025-08-14 | 2026-05-20 |
| Consolidation Radiotherapy vs. Observation in Oligoresidual Advanced Non-Small Cell Lung Cancer After Chemo-Immunotherapy Immunotherapy (with or without chemotherapy) maintenance therapy combined with radiotherapy, Immunotherapy (with or without chemotherapy) maintenance therapy - Non-Small Cell Lung Cancer | Phase 2 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 224 | 2025-06-11 | 2025-07-30 |
| Maintenance Therapy With Selinexor and Azacitidine in TP53 Mutant AML/MDS After Transplantation Maintenance Therapy with Selinexor and Azacitidine - TP53-mutated MDS and AML, Allogeneic Hematopoietic Stem Cell Transplantation | Phase 1 | Active not recruiting | Daihong Liu | 20 | 2025-06-01 | 2025-07-30 |
| Blinatumomab Combined With Venetoclax as Maintenance Therapy After Allo-HSCT in High-risk Ph Negative Acute B-cell Lymphoblastic Leukemia blinatumomab combined with venetoclax as maintenance therapy - B-Cell Acute Lymphoblastic Leukemia, Adult | Phase 2 | Active not recruiting | Zhejiang University | 24 | 2025-06-01 | 2025-09-30 |
Showing 20 of 87. Sign in to see all of them.
Multiple Myeloma (8) · Carcinoma, Non-Small-Cell Lung (6) · Obesity (6) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (6) · Leukemia, Myeloid, Acute (3) · Neoplasm Metastasis (3) · Neoplasm, Residual (3) · Colorectal Neoplasms (2) · Depression (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lung Neoplasms (2) · Lymphoma, B-Cell, Marginal Zone (2) · Lymphoma, Follicular (2) · Lymphoma, Large B-Cell, Diffuse (2) · Lymphoma, Mantle-Cell (2)
Institute of Hematology & Blood Diseases Hospital, China (4) · Sun Yat-sen University (3) · University of Arkansas (3) · University of California, San Francisco (3) · Aretaieion University Hospital (2) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (2) · Children's Cancer Group, China (2) · Fudan University (2) · Navy General Hospital, Beijing (2) · PETHEMA Foundation (2) · Shandong Cancer Hospital and Institute (2) · Abbott (1) · Alvogen Korea (1) · Assistance Publique - Hôpitaux de Paris (1) · Brigham and Women's Hospital (1)
China (24) · United States (22) · Italy (7) · France (6) · Spain (4) · Germany (3) · Greece (3) · South Korea (3) · United Kingdom (3) · Denmark (2) · Poland (2) · Portugal (2) · Brazil (1) · Canada (1) · Chile (1)
Eriphylli Argyra, PhD (2) · Kassiani Theodoraki, PhD, DEAA (2) · Andrea Ravida, DDS MS (1) · Andrei Szigiato, Docteur (1) · Anita Belza, MSci (1) · Anjali S Advani (1) · Anna Sureda, Dr (1) · Artemis Vekrakou, MD (1) · Bart Barlogie, MD, PhD (1) · Bernal Stewart (1) · ChangBeom Lee, M.D., Ph.D. (1) · Changxi Wang, M.D., Ph.D (1) · Chunjie Liu, M.D. (1)
PMID 10438706, PMID 10477976, PMID 10627444, PMID 16421426, PMID 17003366, PMID 18612103, PMID 18669875, PMID 19139435, PMID 19433688, PMID 19711612, PMID 19755674, PMID 19880781, PMID 20018913, PMID 20473362, PMID 20663944, PMID 20679620, PMID 20831669, PMID 21269037, PMID 22058223, PMID 22192060, PMID 22511492, PMID 22897964, PMID 23389497, PMID 23902483, PMID 24117042, PMID 24310847, PMID 24344215, PMID 24475787, PMID 26095785, PMID 26282654, PMID 26668134, PMID 26887549, PMID 27402145, PMID 27789196, PMID 28273702, PMID 28418750, PMID 28787259, PMID 29391341, PMID 29925491, PMID 30328176, PMID 31125101, PMID 31438926, PMID 31859677, PMID 32319233, PMID 32661576, PMID 32730187, PMID 32987765, PMID 34048072, PMID 34709880, PMID 35377708
2014 (1), 2015 (1), K01MH113475 (1), P20MD002329 (1), R01AG084527 (1), R01DA047867 (1), R01HD072573 (1), R01HL104147 (1), R01MH116050 (1), R01MH116052 (1), R01MH116061 (1), R01MH116062 (1), R33HL151978 (1)